[Skip to Content]
[Skip to Content Landing]
Citations 0
Editor's Correspondence
June 27, 2005

Inconsistency in the Editorial Process in Archives of Internal Medicine?—Reply

Arch Intern Med. 2005;165(12):1440. doi:10.1001/archinte.165.12.1440-a

In reply

We completely agree with Bjarnason. The APC trial indicates that no selective cyclooxygenase-2 (COX-2) inhibitor is risk free, but the bulk of the available evidence suggests that celecoxib in routinely used doses (eg, up to 200 mg/d) has a lower risk of cardiovascular toxic effects compared with rofecoxib or valdecoxib.

 

 

 

 

Correspondence: Dr Solomon, Harvard Medical School, Division of Pharmacoepidemiology, Brigham and Women’s Hospital, 1620 Tremont St, Suite 3030, Boston, MA 02120 (dhsolomon@partners.org).

First Page Preview View Large
First page PDF preview
First page PDF preview
×